Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Magali Laprise-Lachance"'
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4118-4128 (2021)
The most common adverse reactions to rituximab are infusion-related reactions (IRR). We evaluated the efficacy of split dosing the first rituximab infusion over two days to reduce IRR incidence in patients with hematological cancer and a high lymphoc
Externí odkaz:
https://doaj.org/article/133b16f81ece44638a284f7851393b87
Publikováno v:
Current Oncology, Vol 28, Iss 349, Pp 4118-4128 (2021)
Current Oncology
Volume 28
Issue 5
Pages 349-4128
Current Oncology
Volume 28
Issue 5
Pages 349-4128
The most common adverse reactions to rituximab are infusion-related reactions (IRR). We evaluated the efficacy of split dosing the first rituximab infusion over two days to reduce IRR incidence in patients with hematological cancer and a high lymphoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796da29f0013c77949ba161148c4b8ce
https://doi.org/10.3390/curroncol28050349
https://doi.org/10.3390/curroncol28050349
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1638-1644
Objectives To estimate the relative risk of pulmonary toxicity in patients exposed to a bleomycin-based chemotherapy including filgrastim compared to a similar chemotherapy without filgrastim. Methods We conducted a nested case–control study of pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af724c9205fcbf99a0db81c33bcc8a8d
https://doi.org/10.1177/1078155218804293
https://doi.org/10.1177/1078155218804293